Rosuvastatin attenuated contrast-induced nephropathy in diabetes patients with renal dysfunction

International Journal of Clinical and Experimental Medicine

Volumn 8, Issue 2, 2015, Pages 2342-2349

  Qiao, Bing ^a   Deng, Jie ^b   Li, Yi ^b   Wang, Xiaozeng ^b   Han, Yaling ^b  

^a The Chinese People’s Liberation Army ^*  (China)

^b GENERAL HOSPITAL OF NORTHERN THEATER COMMAND   (China)

Author keywords

Acute; Antilipemic agents; Contrast media; Kidney failure; Rosuvastatin

Indexed keywords

CHOLESTEROL; CREATININE; CYSTATIN; IODIXANOL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; N ACETYL BETA GLUCOSAMINIDASE; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; ROSUVASTATIN;

ADULT; ARTICLE; CONTRAST INDUCED NEPHROPATHY; DIABETIC PATIENT; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; KIDNEY FAILURE; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

EID: 84926300986     PISSN: None     EISSN: 19405901     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. [1] Bartholmew BA, Harjai KJ, Dukkipati S, Boura JA, Yerkey MW, Glazier S, Grines CL, O’Neill WW. Impact of nephropathy after percutane­ous coronary intervention and a method for risk stratification. Am J Cardiol 2004; 93: 1515-1519.
2. [2] McCullough PA. Contrast-induced acutet kid­ney injury. J Am Coll Cardiol 2008; 51: 1419-1428.
3. [3] Attallah N, Yassine L, Musial J, Yee J, Fisher K. The potential role of statins in contrast ne­phropathy. Clin Nephrol 2004; 62: 273-278.
4. [4] Xinwei J, Xianghua F, Jing Z, Xinshun G, Ling X, Weize F, Guozhen H, Yunfa J, Weili F, Shiqiang L. Comparison of usefulness of simvastatin 20 mg versus 80 mg in preventing contrast-in­duced nephropathy in patients with acute cor­onary syndrome undergoing percutaneous coronary intervention. Am J Cardiol 2009; 104: 519-524.
5. Jo SH, Koo BK, Park JS, Kang HJ, Cho YS, Kim YJ, Youn TJ, Chung WY, Chae IH, Choi DJ, Sohn DW, Oh BH, Park YB, Choi YS, Kim HS. Preven­tion of radiocontrast medium-induced ne­phropathy using short-term high-dose simvas­tatin in patients with renal insufficiency undergoing coronary angiography (PROMISS) trial-a randomized controlled study. Am Heart 2008; 155: 499.411-499.e8.
6. [6] Wassmann S, Laufs U, Baumer AT, Müller K, Ahlbory K, Linz W, Itter G, Rösen R, Böhm M, Nickenig G. HMG-CoA reductase inhibitors im­prove endothelial dysfuncfion in normocholes­terolemic hypertension via reduced production of reactive oxygen species. Hypertension 2001; 37: 1450-1457.
7. [7] Hernández-Perera O, Pérez-Sala D, Navarro-Antolín J, Sánchez-Pascuala R, Hernández G, Díaz C, Lamas S. Effects of the 3-hydroxy-3-methylglutaryl CoA reductase inhibitors, atorvastatin and sinvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. J Clin Invest 1998; 101: 2711-2719.
8. [8] Kunieda Y, Nakagawa K, Nishimura H, Kato H, Ukimura N, Yano S, Kawano H, Kimura S, Nakagawa M, Tsuji H. HMG-CoA reductase inhibitor suppresses the expression of tissue factor and plasminogen activator inhibitor-1 induced by angiotensin II in cultured rat aortic endothelial cells. Thromb Res 2003; 110: 227-234.
9. [9] Poletti PA, Saudan P, Platon A, Mermillod B, Sautter AM, Vermeulen B, Sarasin FP, Becker CD, Martin PY. IV N-Acetylcysteine and Emer­gency CT: Use of Serum Creatinine and Cys­tatin C as Markers of Radiocontrast Nephrotox­icity. Am J Radiology 2007; 189: 687-692.
10. [10] Hoste EA, Damen J, Vanholder RC, Lameire NH, Delanghe JR, Van Den Hauwe K, Colardyn FA. Assessment of renal function in recently admitted critically ill patients with normal se­rum creatinine. Nephrol Dial Transplant 2005; 20: 747-753.
11. [11] Dharnidharka VR, Kwon C, Stevens G. Serum cystatin C is superior to serum creatinine as a marker of kidney function: A meta-analysis. Am J Kidney Dis 2002; 40: 221-226.
12. [12] Herget-Rosenthal S, Marggraf G, Husing J, Göring F, Pietruck F, Janssen O, Philipp T, Kribben A. Early detection of acute renal failure by serum cystatin C. Kidney Int 2004; 66: 1115-1122.
13. [13] Ling W, Zhaohui N, Ben H, Leyi G, Jianping L, Huili D, Jiaqi Q. Urinary IL-18 and NGAL as early predictive biomarkers in contrast-induced ne­phropathy after coronary angiography. Nephron Clin Pract 2008; 108: c176-c181.
14. [14] McCullough PA, Adam A, Becker CR, Davidson C, Lameire N, Stacul F, Tumlin J; CIN Consen­sus Working Panel. Risk prediction of contrast-induced nephropathy. Am J Cardiol 2006; 98: 27-36.
15. [15] King SB, Smith SC Jr., Hirshfeld JW Jr., Ja­cobs AK, Morrison DA, Williams DO; 2005 WRITING COMMITTEE MEMBERS, Feldman TE, Kern MJ, O’Neill WW, Schaff HV, Whitlow PL, Adams CD, Anderson JL, Buller CE, Creager MA, Ettinger SM, Halperin JL, Hunt SA, Krum­holz HM, Kushner FG, Lytle BW, Nishimura R, Page RL, Riegel B, Tarkington LG, Yancy CW. 2007 Focused update of the ACC/AHA/SCAI 2005 guileline update for percutaneous coro­nary intervention. Circulation 2008; 117: 261-95.
16. [16] Ma YC, Li Z, Chen JH, Luo Q, Yu XQ, Li Y, Xu JS, Huang SM, Wang LN, Huang W, Wang M, Xu GB, Wang HY. Modified glomeruar filtration rate estimating equation for Chinese patients with chronic kidney disease. J Am Soc Nephrol 2006; 17: 2937-2944.
17. [17] Thomsen HS. Guidelines for contrast media from the European Society of Urogenital Radi­ology. Am J Roentgenol 2003; 181: 1463-1471.
18. [18] Patti G, Nusca A, Chello M, Pasceri V, D’Ambrosio A, Vetrovec GW, Di Sciascio G. Use­fulness of statin pretreatment to prevent con­trast-induced nephropathy and to improve long-term outcome in patients undergoing per­cutaneous coronary intervention. Am J Cardiol 2008; 101: 279-285.
19. [19] Khanal S, Attallah N, Smith DE, Kline-Rogers E, Share D, O’Donnell MJ, Moscucci M. Statin therapy reduces contrast-induced nephropa­thy: An analysis of contemporary percutaneous interventions. Am J Med 2005; 118: 843-849.
20. [20] Toso A, Maioli M, Leoncini M, Gallopin M, Tedeschi D, Micheletti C, Manzone C, Amato M, Bellandi F. Usefulness of Atorvastatin (80 mg) in prevention of contrast-induced nephropathy in patients with chronic renal disease. Am J Car­diol 2010; 105: 288-292.
21. [21] Vaidya VS, Waikar SS, Ferguson MA, Collings FB, Sunderland K, Gioules C, Bradwin G, Matsouaka R, Betensky RA, Curhan GC, Bonventre JV. Urinary biomarkers for sensitive and specific detection of acute kidney injury in hu­mans. Clin Transl Sci 2008; 1: 200-208.
22. [22] Bachorzewska-Gajweska H, Malyszko J, Sitniewska E, Malyszko JS, Dobrzycki S. Neutrophil gelatinase-associated lipocalin and renal function after percutaneous coronary interven­tions. Am J Nephrol 2006; 26: 287-292.
23. [23] Bachorzewska-Gajweska H, Malyszko J, Sitniewska E, Malyszko JS, Dobrzycki S. Neutrophil gelatinase-associated lipocalin (NGAL) correlations with cystatin C, serum creatinine and eGFR in patients with normal serum cre­atinine undergoing coronary angiography. Nephrol Dial Transplant 2007; 22: 295-296.
24. [24] Bachorzewska-Gajweska H, Malyszko J, Sitniewska E. Could neutrophil gelatinase-associ­ated lipocalin and cystatin C predict the devel­opment of contrast-induced nepropathy after percutaneous coronary interventions in pa­tients with stable angina and normal serum, Creatinine values? Kidney Blood Press Res 2007; 30: 408-415.
25. [25] Hirsch R, Dent C, Pfriem H, Allen J, Beekman RH, Ma Q, Dastrala S, Bennett M, Mitsnefes M, Devarajan P. NGAL is an early predict biomarker of contrast-induced nepropathy in children. Pediatr Nephrol 2007; 22: 2089-2095.
26. [26] Ling W, Zhaohui N, Ben H, Leyi G, Jianping L, Huili D, Jiaqi Q. Urinary IL-18 and NGAL as early predictive biomarkers in contrast-induced ne­phropathy after coronary angiography. Neph­ron Clin Pract 2008; 108: c176-c181.
27. [27] Rehman T, Fought J, Solomon R. N-acetylcyste­ine effect on serum creatinine and cystatin C levels in CKD patients. Clin J Am Soc Nephrol 2008; 3: 1610-1614.
28. [28] Waikar S, Liu KD, Chertow GM. Diagnosis, epi­demiology and outcomes of acute renal fail­ure. Clin J Am Soc Nephrol 2008; 3: 844-861.
29. [29] Chen GL, Su JZ. Atorvastatin attenuated con­trast induced renal function damage. Clin J Cardiol 2009; 37: 389-393.